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Abstract
Background: Chronic infections and associated inflammatory markers are suggested risk factors for cardiovascular
disease (CVD). The proinflammatory cytokine, interleukin (IL)-1b, is suggested to play a role in the regulation of
local inflammatory responses in both CVD and periodontitis. The leukotoxin from the periodontal pathogen
Aggregatibacter actinomycetemcomitans has recently been shown to cause abundant secretion of IL-1b from
macrophages. The aim of the present study was to compare the prevalence of systemic immunoreactivity to
A. actinomycetemcomitans leukotoxin in myocardial infarction (MI) cases (n = 532) and matched controls
(n = 1,000) in a population-based case and referents study in northern Sweden.
Methods: Capacity to neutralize A. actinomycetemcomitans leukotoxin was analyzed in a bioassay with leukocytes,
purified leukotoxin, and plasma. Plasma samples that inhibited lactate-dehydrogenase release from leukotoxin-lysed
cells by ≥50% were classified as positive.
Results: Neutralizing capacity against A. actinomycetemcomitans leukotoxin was detected in 53.3% of the plasma
samples. The ability to neutralize leukotoxin was correlated to increasing age in men (n = 1,082) but not in women
(n = 450). There was no correlation between presence of systemic leukotoxin-neutralization capacity and the
incidence of MI, except for women (n = 146). Women with a low neutralizing capacity had a significantly higher
incidence of MI than those who had a high neutralizing capacity.
Conclusion: Systemic immunoreactivity against A. actinomycetemcomitans leukotoxin was found at a high
prevalence in the analyzed population of adults from northern Sweden. The results from the present study do not
support the hypothesis that systemic leukotoxin-neutralizing capacity can decrease the risk for MI.
Background
Chronic inflammations, such as periodontitis, are sug-
gested to be risk factors for the development of cardio-
vascular diseases [1]. It has been suggested that the total
pathogenic burden from the oral cavity, and possibly
also from the gut, correlates with disease markers of
atherosclerosis [2]. Periodontitis is a bacteria-induced
inflammatory condition that causes degradation of the
tooth-supporting tissues, bone and connective tissue
[3,4]. Bioactive molecules released from pathogenic
microorganisms located in the subgingival biofilm cause
imbalance in the inflammatory response, which results
in loss of the tooth-supporting tissues [5]. For the host
to maintain homeostasis within the periodontal tissues,
the immune response system contributes to controlling
the microbial colonization and invasion [6]. This
immune response includes local and systemic produc-
tion of antibodies induced by antigens from the micro-
organisms that are localized in this biofilm [7]. There
are more than 700 different microbial species found in
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pyrosequencing methodology to analyze the composition
of the oral microbiota indicate a substantial increase in
that number [9]. Among the different species found,
Aggregatibacter actinomycetemcomitans is a bacterium
associated with aggressive forms of periodontitis, and it
produces a leukotoxin that specifically affects human
leukocytes [10]. Individuals infected with a specific,
highly leukotoxic clone (JP2) of this bacterium have a
significantly increased risk for periodontitis [11]. The
proinflammatory response induced by the leukotoxin is
a cellular response associated with the pathogenesis of
periodontitis [10,12,13] and atherosclerosis [14].
The proportion in a population that harbor A. acti-
nomycetemcomitans varies depending on geographic
origin and periodontal condition of the subjects [10]. It
has been shown that systemic leukotoxin-neutralization
is correlated to the presence of this bacterium in the
oral subgingival biofilm [15-17]. Data from a previous
study showed that women with systemic neutralizing
capacity against A. actinomycetemcomitans’ leukotoxin
had a significantly decreased incidence of stroke [18].
This systemic neutralizing capacity has been shown to
correlate (p-value < 0.001) to the presence of leuko-
toxin-specific antibodies, as well as to antibodies
against whole A. actinomyctemcomitans bacteria [19].
We hypothesized that a virgin A. actinomycetemcomi-
tans infection late in life might be a risk factor for
stroke and contribute to the negative association
between stroke and the presence of these neutralizing
a n t i b o d i e s .T h ea i mo ft h ep r e s e n ts t u d yw a st oa n a -
lyze if the presence of systemic immunoreactivity to
A. actinomycetemcomitans leukotoxin also interferes
with the incidence of a future myocardial infarction (MI).
Methods
Study population
The study population was derived from the Northern
Sweden Health and Disease Study (NSHDS), which con-
sists of three sub-cohorts: The Västerbotten Intervention
Programme (VIP) [20], the WHO’s Multinational Moni-
toring of Trends and Determinants in Cardiovascular
Disease (MONICA) study in northern Sweden [21] and
the Mammography Screening Project (MSP) [22]. Both
VIP and MONICA are health examination programmes
for CVD and diabetes. Participation rates were 59 and
77%, respectively. The VIP was designed to be as similar
as possible to the MONICA study. In order to increase
the number of female cases, participants in the MSP
were included in sex specific analyses. The participation
rate in the MSP was 85% in the screening phase, of
which 57% donated blood samples. By December 31,
1999 approximately 73,000 unique subjects had been
screened in these 3 sub-cohorts in NSHDS.
Incident cases and matching controls were identified
through 13 years of follow-up (1985-1999) from the
Västerbotten Intervention Program and the Multina-
tional Monitoring of Trends and Determinants in Cardi-
ovascular Disease (MONICA) study. Study participants
were from the Västerbotten and Norrbotten counties in
northern Sweden. Participants with a history of MI,
stroke or cancer were excluded from this study. Partici-
pants were followed from baseline examination until
first MI or death. There was an average time period of
4 years between the time of inclusion and the MI event.
Fatal and nonfatal cases of MI occurring from October
1, 1994 to December 31, 1999 were identified through
the Northern Sweden Monica Incidence Registry [23].
Throughout the follow-up period, 532 incident first
events of MI (cases) were identified. For each case, two
controls were individually matched for age, sex and ± 4
months of case occurrence. Thus, the study population
consisted of 1,532 participants, 532 cases (382 men and
156 women) and 1,000 sex and age-matched controls
(706 men and 294 women), aged 30-77 years at baseline.
This study population has previously been described in
detail [24]. The study was approved by the Ethics Com-
mittee of Umeå University and was conducted in accor-
dance with the Helsinki Declaration. All participants
gave informed consent.
Leukotoxin-neutralization assay
The A. actinomycetemcomitans leukotoxin-neutralizing
capacity in the plasma samples was detected as a reduc-
tion of leukocyte damage and subsequent leakage of lac-
tate dehydrogenase (LDH) upon exposure to purified
leukotoxin, as described previously [18]. This assay
quantifies the activity of the LDH enzyme and does not
allow freezing and thawing of the supernatants. The
neutralization assay also limits the possible influence
from LDH present in the different plasma samples from
the study population.
Briefly, human polymorphonuclear leukocytes (PMNs)
were isolated from human peripheral blood as described
previously [25]. The isolated PMNs were suspended in
RPMI 1640 (Sigma-Aldrich, St Louis, MI, USA) with
10% fetal bovine serum (FBS) (Sigma-Aldrich) at a den-
sity of 3 × 10
6 cells/ml. The blood was taken from
donors visiting the University Hospital blood bank in
Umeå, Sweden. Informed written approval was given by
all subjects, and authorization for the study was granted
by the Human Studies Ethical Committee of Umeå Uni-
versity, Sweden (§67/3, dnr 03-019).
For detection of leukotoxin-neutralizing capacity, puri-
fied leukotoxin (450 ng/mL) [26] was mixed with each
plasma sample (10%) in RPMI 1640. One hundred μl
portions of the plasma-leukotoxin mixtures were added
in duplicate to a 96 well culture plate (Nunc, Roskilde,
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ture. Then 50 μl of PMN was added and the mixtures
were incubated for 60 min at 37°C in 5% CO2.A c t i v i t y
of the released LDH into the culture supernatant was
quantified as described previously [25]. Plasma samples
that inhibited the leukotoxin-induced LDH release by
≥50% were classified as positive and were further ana-
lyzed in the assay diluted to 1% of the final volume.
Plasma without leukotoxin-neutralization capacity was
classified as “null”, plasma that neutralized leukotoxin at
10% plasma concentration but not at 1% was classified
as “low“, and plasma that neutralized the leukotoxin at
both 10% and 1% concentrations was classified as “high”.
Statistical anaylses
The Mantel-Haenszel c
2-test for trend was used to ana-
lyze the association between age and antibodies. To
investigate if the presence of leukotoxin antibodies
(categorized into null, low or high) affects the risk of
having an MI, conditional logistic regression appropriate
for the matched design, was used. A multivariable
model was used to adjust for smoking, self-reported dia-
betes, systolic blood pressure and apoB/apoA1. Results
are presented as p-values, odds ratios (ORs) and corre-
sponding 95% confidence intervals (CIs). No correction
for multiple testing was performed. SAS version 9.1 was
used for the statistical analyses.
Results
Prevalence of leukotoxin-neutralizing capacity
The study population was classified into 4 different age
groups, and the distribution in relation to age and gen-
der is shown in Figure 1.
Among the 1,532 analyzed plasma samples, 817
(53.3%) could neutralize A. actinomycetemcomitans leu-
kotoxicity in the neutralization assay. Further dilution of
the plasma samples resulted in loss of the capacity to
neutralize leukotoxin in 526 of these samples, and they
were classified as samples with low neutralizing capacity.
The 291 samples that neutralized leukotoxin also at the
higher dilution were classified as high. The distribution
of the study population in relation to their systemic
capacity to neutralize leukotoxin was 46.7% negative,
34.3% low and 19.9% high. There were no significant
differences between men and woman in capacity to neu-
tralize the leukotoxin (Figure 2).
Prevalence and age
The proportion of subjects with capacity to neutralize
leukotoxin increased with increasing age (Figure 3). This
age-related increase was significant for men (p-values ≤
0.001) but not for women (p-values = 0.170). In order
to avoid combinations with no or few observations, the
two lowest age groups (29-44 and 45-54) were merged
for women, and the two highest age groups (55-64 and
65-77) were merged for men in the formal analysis.
Prevalence in relation to incidence of MI
Women with low capacity to neutralize leukotoxin had a
significantly (p-value = 0.031) higher incidence of MI
than women without the capacity to neutralize leuko-
toxin (Table 1). The odds ratio (OR) of having an MI in
this group was 1. 8 (95% CI: 1.13-2.8). No other signifi-
cant differences were seen between the incidence of MI
and the different groups classified in relation to systemic
leukotoxin neutralization and gender. After adjustments
for other known risk-factors for MI (smoking, diabetes,
systolic blood pressure and ApoB/ApoA1) there were no
significant differences (Table 1).
Discussion
Results from the present study showed that 53.3% of the
plasma samples from a Swedish adult cohort of 1,532
subjects had the capacity to neutralize A. actinomycetem-
comitans leukotoxin. It has recently been demonstrated
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Figure 1 Distribution of men and women in the age groups for
the whole study cohort, i.e. including both cases and referents.
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Figure 2 Proportion of men and women with different
systemic capacity to neutralize A. actinomycetemcomitans
leukotoxin.
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the presence of leukotoxin-specific antibodies [19]. The
high prevalence of subjects with this leukotoxin-neutra-
lizing capacity was not expected, however, in line with
results from some previous studies [19,27]. Both of these
studies were based on Swedish study populations from a
similar age group as examined in the present study. In
one of these reports the study population consisted of a
total of 197 subjects from a case control study of myocar-
dial infarction and matched healthy controls, and the
prevalence of systemic leukotoxin-neutralizing capacity
was 57% without significant differences between cases
and controls [19,28]. The other study consisted of 50
subjects with periodontitis and 41 healthy referents, and
in this population the prevalence of systemic leukotoxin-
neutralizing capacity was 45% without significant differ-
ences between the two groups [27]. Another study
showed lower prevalence (15.2%) of leukotoxin-neutraliz-
ing capacity [18]. In this study [18] a target cell line (HL-
60) with lower sensitivity to leukotoxin than the PMNs
was used in the neutralization assay [29], which resulted
in a need for enhanced leukotoxin concentration to
obtain cell lyses and subsequently more antibodies for
neutralization. This difference in leukotoxin sensitivity
makes this assay with PMNs more sensitive to detect leu-
kotoxin neutralization than the previous used assay with
HL-60 cells [15]. The proportion of samples (19.9%) with
high leukotoxin-neutralizing capacity in the present
study might be comparable with the results from Johans-
son et al., 2005 [18].
We have previously shown that the systemic leuko-
toxin-neutralizing capacity correlated to a decreased
incidence of stroke in women [18]. The mechanisms
behind this phenomenon are not known. We speculate
that a virgin infection with A. actinomycetemcomitans in
middle-aged and elderly subjects might be a risk factor
for stroke and that the capacity to neutralize leukotoxin
might be protective. The leukotoxin has been shown to
induce a rapid proinflammatory reaction in human
macrophages, already at a ratio of 1 bacterium/macro-
p h a g e[ 1 3 ] ,a n dt h e r e f o r et h el e u k o t o x i ni sap o s s i b l e
risk factor in atherosclerosis. The common etiology of
both stroke and MI with inflammatory processes and
atherosclerosis [14], indicates that the presence of sys-
temic leukotoxin-neutralizing capacity also might inter-
fere with the incidence of MI. The results of the present
study showed that systemic presence of leukotoxin-
neutralizing capacity did not affect the incidence of MI,
except for women classified as low for this neutralizing
capacity. Our main finding refutes the hypothesis that
systemic immunoreactivity to leukotoxin has a protec-
tive effect against MI. The significant association found
for women might be an effect of multiple testing or a
type-1 error, but further studies on this finding are war-
ranted to confirm this association.
The periodontal status of the analyzed subjects is not
known, but it could be expected to be in line with a
similar recently examined Swedish population [28]. In
that population a correlation between MI and periodon-
titis was observed. In addition, both periodontitis and
MI correlated to the presence of systemic immunoreac-
tivity against Porphyromonas gingivalis but not against
A. actinomycetemcomitans [19,28].
The proportion of subjects with systemic neutralizing
capacity to leukotoxin increased with increasing age,
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Figure 3 Proportion of men and women (low + high) with
systemic A. actinomycetemcomitans leukotoxin-neutralizing
capacity in relation to age. The distributions of men and women
in the different groups were: 29-44 yr, 179 men and 21 women;
45-54 yr, 397 men and 114 women; 55-64 yr, 503 men and 221
women; and 65-77 yr, 6 men and 94 women.
Table 1 Proportion of controls and cases with plasma
that neutralized leukotoxic activity
Men & Women Neg Low High
Control 47.1% (471) 33.3% (333) 19.6% (196)
Case 45.9% (244) 36.3% (193) 17.9% (95)
OR 1.1 (0.8-1.4) 0.9 (0.7-1.2)
adjusted OR 1.0 (0.7-1.4) 1.3 (0.9-2.0)
Women Neg Low High
Control 51.7% (152) 28.6% (84) 19.7% (58)
Case 42.9% (67) 39.7%*(62) 17.3% (27)
OR 1.8* (1.1-2.8) 1.0 (0.8-1.3)
adjusted OR
# 1.2 (0.5-2.9) 1.4 (0.5-4.3)
Men Neg Low High
Control 45.2% (319) 35.3% (249) 19.5% (138)
Case 47.1% (177) 34.8% (131) 18.1% (68)
OR 0.9 (0.7-1.2) 0.8 (0.6-1.2)
adjusted OR
# 1.0 (0.7-1.4) 1.3 (0.9-2.1)
Significant differences between controls and cases (*), number of subjects (n)
and the odds ratio (OR) of having an MI compared with the antibody-negative
group (null) are indicated.
#) Adjusted for smoking, self-reported diabetes, systolic blood pressure and
ApoB/ApoA1.
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related increase is in line with previous findings [19]
and indicates that a virgin infection with A. actinomyce-
temcomitans can take place late in life. A virgin A. acti-
nomycetemcomitans infection might decrease the risk
for stroke in middle-aged and elderly subjects without
systemic leukotoxin-neutralizing capacity [18]. Even
though the role of leukotoxin-neutralizing antibodies in
the pathogenesis of periodontal disease is unknown [7],
the antibodies might help mitigate the systemic effects
of A. actinomycetemcomitans infections. The leukotoxin
produced by A. actinomycetemcomitans is a unique viru-
lence factor with the capacity to cause a rapid proin-
flammatory reaction [10]. However, to fully investigate a
potential role of leukotoxin in the pathogenesis of
stroke, the presence of systemic leukotoxin antibodies
has to be analyzed both before and after the disease
incidence. We therefore still look at the results that
showed a negative correlation between systemic leuko-
toxin antibodies and stroke as preliminary [18].
Conclusions
The results from the present study do not support the
hypothesis that systemic leukotoxin-neutralizing capacity
can decrease the risk for MI. In addition, the prevalence
of systemic A. actinomycetemcomitans leukotoxin-
neutralizing capacity is high (53.3%) in adults from
northern Sweden. The prevalence of leukotoxin-neutra-
lizing capacity increased with increasing age, significantly
for men but not for women.
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